Skip to main content

Table 3 Subgroup analysis using Cox proportional hazard model by age, insurance coverage, average pharmaceutical expenditures, region, and number of medical centers

From: Are sleep disorders associated with increased mortality in asthma patients?

 

HR

95% CI

P-value

Lower

Upper

Age (years)

    

 ≤29

7.351

1.735

31.139

0.0068

 30–59

1.415

0.865

2.313

0.1665

 ≥60

1.301

1.097

1.543

0.0025

Insurance coverage

    

 Medical aid

0.690

0.316

1.508

0.3518

 NHI, self-employed insured

1.647

1.305

2.078

<0.0001

 NHI, employee insured

1.327

1.083

1.626

0.0063

Average annual pharmaceutical expenditures for asthma

   

 Below median

1.447

1.116

1.876

0.0052

 Above median

1.466

1.229

1.751

<0.0001

Region

    

 Metropolitan

1.370

1.087

1.727

0.0078

 Other

1.508

1.248

1.825

<0.0001

Number of medical centers per 1000 residents

    

 Below median

1.609

1.302

1.988

<0.0001

 Above median

1.323

1.079

1.622

0.0071

Charlson comorbidity index

    

 ≤2

1.359

1.148

1.610

0.0004

 ≥3

1.553

1.020

2.364

0.0401

  1. CI confidence interval; HR hazard ratio; NHI National Health Insurance. The results of the subgroup analysis to investigate differences in the association between sleep disorders and mortality according to age, insurance coverage, average annual pharmaceutical expenditures for asthma, region, number of medical centers, and Charlson comorbidity index. The P-value in type 3 tests for models with interactions between sleep disorders and subgroup variables were as follows: model with interaction between age and sleep disorders, P-value in type 3 test = 0.2249; model with interaction between insurance coverage and sleep disorders, P-value in type 3 test = 0.1742; model with interaction between average annual pharmaceutical expenditures for asthma and sleep disorders, P-value in type 3 test = 0.4199; model with interaction between region and sleep disorders, P-value in type 3 test = 0.3216; model with interaction between number of medical centers and sleep disorders, P-value in type 3 test = 0.6448; model with interaction between Charlson comorbidity index and sleep disorders, P-value in type 3 test = 0.0427